Literature DB >> 18356031

Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus.

Anca Maria Cimpean1, Marius Raica, Svetlana Encica, Remus Cornea, Viorica Bocan.   

Abstract

Vascular endothelial growth factor A (VEGF-A) is an angiogenic growth factor that is a primary stimulant of the vascularization of solid tumors. In the tumor microenvironment, an upregulation of both VEGF and its receptors occurs, leading to a high concentration of occupied receptors on tumor vascular endothelium. Also, VEGF is involved in the development of the normal vascular network of the thymus. Little is known about VEGF expression in normal and malignant thymic tissue. Our purpose was to study the pattern and localization of VEGF expression in benign conditions of the thymus and thymoma to determine a possible correlation with VEGF receptors VEGFR1, VEGFR2 and microvascular density. All cases were positive for VEGF and VEGFR1, 2 in the epithelial cells, in a cytoplasmic, granular pattern. In the normal thymus, there were positive epithelial cells with subcapsular distribution and Hassall's corpuscle epithelial cells. In acute thymic involution, the positive fields were correlated with dilation and stasis of blood vessels and lymphocyte depletion. Rare positive cells were found in other types of involution; the myasthenic thymus showed an intense and diffuse reaction in lymphoid follicles of the medulla. A strong reaction for VEGF was observed in type B3 thymomas in neoplastic epithelial cells, normal endothelial cells, plasma within the blood vessels and focally in the stroma adjacent to the tumor. Receptors for VEGF were positive in neoplastic epithelial cells and endothelium. We hypothesized that VEGF acts as an immunoregulatory factor in the normal thymus and as proangiogenic and autocrine factor in thymomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18356031     DOI: 10.1016/j.aanat.2007.05.003

Source DB:  PubMed          Journal:  Ann Anat        ISSN: 0940-9602            Impact factor:   2.698


  21 in total

1.  Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults.

Authors:  Ioannis Politikos; Haesook T Kim; Theodoros Karantanos; Julia Brown; Sean McDonough; Lequn Li; Corey Cutler; Joseph H Antin; Karen K Ballen; Jerome Ritz; Vassiliki A Boussiotis
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-21       Impact factor: 5.742

Review 2.  Management of thymic tumors: a European perspective.

Authors:  Enrico Ruffini; Federico Venuta
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

3.  Platelet-derived growth factor and platelet-derived growth factor receptor-α expression in the normal human thymus and thymoma.

Authors:  Anca Maria Cimpean; Raluca Ceauşu; Svetlana Encică; Pusa Nela Gaje; Domenico Ribatti; Marius Raica
Journal:  Int J Exp Pathol       Date:  2011-06-07       Impact factor: 1.925

Review 4.  Thymic malignancies: from clinical management to targeted therapies.

Authors:  Ronan J Kelly; Iacopo Petrini; Arun Rajan; Yisong Wang; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

5.  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

Authors:  Anish Thomas; Arun Rajan; Arlene Berman; Yusuke Tomita; Christina Brzezniak; Min-Jung Lee; Sunmin Lee; Alexander Ling; Aaron J Spittler; Corey A Carter; Udayan Guha; Yisong Wang; Eva Szabo; Paul Meltzer; Seth M Steinberg; Jane B Trepel; Patrick J Loehrer; Giuseppe Giaccone
Journal:  Lancet Oncol       Date:  2015-01-13       Impact factor: 41.316

Review 6.  Novel Agents in the Treatment of Thymic Malignancies.

Authors:  Claire Merveilleux du Vignaux; Jean-Michel Maury; Nicolas Girard
Journal:  Curr Treat Options Oncol       Date:  2017-08-10

7.  Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.

Authors:  Thomas Neuhaus; Joachim Luyken
Journal:  Target Oncol       Date:  2012-10-23       Impact factor: 4.493

8.  Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E.

Authors:  Chiara Catania; Fabio Conforti; Gianluca Spitaleri; Massimo Barberis; Lorenzo Preda; Cristina Noberasco; Chiara Lazzari; Francesca Toffalorio; Filippo de Marinis; Michela Manzotti; Tommaso Martino De Pas
Journal:  Onco Targets Ther       Date:  2014-05-08       Impact factor: 4.147

9.  Alterations of Thymic Epithelial Cells in Lipopolysaccharide-induced Neonatal Thymus Involution.

Authors:  Yong-Jie Zhou; Hua Peng; Yan Chen; Ya-Lan Liu
Journal:  Chin Med J (Engl)       Date:  2016-01-05       Impact factor: 2.628

10.  Genome-wide association study reveals novel loci for litter size and its variability in a Large White pig population.

Authors:  E Sell-Kubiak; N Duijvesteijn; M S Lopes; L L G Janss; E F Knol; P Bijma; H A Mulder
Journal:  BMC Genomics       Date:  2015-12-09       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.